Skip to main content
Independent peptide information No peptide sales Sources shown

Editorial boundary

What we do not publish, and why

We publish evidence, testing limits, safety signals and official-source routes. We exclude dosing, cycles, stacks, reconstitution, injection technique, sourcing, seller rankings, evasion content and personalised medical advice.

The editorial boundary keeps What’s in the Vial? focused on checking claims and reducing harm. Content that could function as a use protocol, purchasing route, seller promotion or anti-doping evasion guide falls outside the publication.

We can report a dose used in a cited study when it is necessary to understand the evidence. We do not turn that study detail into instructions for an individual reader or a product of uncertain identity and quality.

Where the editorial line sits

Each excluded category has a corresponding form of information that the site can publish without becoming a protocol or sales route.

Excluded

Dosing, cycles and stacks

No dose recommendations, schedules, combinations, escalation plans or cycle design for experimental products.

Published instead

Trial design and evidence scope

Study doses may be reported as evidence, with route, population, outcome and limits kept in the same passage.

Excluded

Reconstitution and injection technique

No mixing calculations, preparation steps, injection instructions or equipment guides.

Published instead

Product-quality and safety uncertainty

We explain why identity, quantity, sterility and endotoxin require separate evidence and what remains unmeasured.

Excluded

Sourcing and supplier comparisons

No where-to-buy guidance, seller rankings, referral links, discount codes or claims that one grey-market source is safe.

Published instead

Publisher and document checks

We show how to verify the source, read a certificate and identify the commercial incentives behind guidance.

Excluded

Detection windows and masking

No content designed to avoid testing, disguise use or work around anti-doping rules.

Published instead

Current sport status

We route athletes to the current Prohibited List, exact substance naming and safe reporting information.

Excluded

Personalised medical advice

No diagnosis, treatment plan or individual risk assessment based on a message, product page or uploaded document.

Published instead

General evidence and safe-action routes

We state known harms, suspected signals, unmeasured risk and when official or urgent help routes apply.

Why can a study dose appear on the site?

A dose can be part of the intervention studied, so removing it could distort the evidence. We report it only when needed to describe the study and keep it attached to the route, population, comparator, outcome and study limits.

A trial dose does not become a recommendation. It cannot establish the contents, concentration, sterility or suitability of a vial obtained outside that study.

Evidence detail, not a protocol

The site does not convert trial methods into instructions, calculators, schedules or individual advice.

Why exclude practical use instructions?

A protocol can assume a product identity, quantity and quality that the available evidence has not established. The gap becomes more serious when a vial is research-labelled, unauthorised or obtained through an unverified supply route.

The site's role is to show the gap between the claim and the evidence, including how the evidence method records unknowns.

Why exclude supplier rankings?

A seller comparison would pull the publication into the market it is assessing. Referral income, paid inclusion and discount codes would also create incentives to soften evidence and safety language. The funding and conflicts policy excludes those relationships.

Why exclude personalised medical advice?

A safe individual assessment requires information and professional responsibility that a general publication does not hold. An article or uploaded certificate cannot replace clinical history, examination, diagnosis or a regulated professional's duty of care.

Why exclude evasion content?

Athletes and support personnel need current status information, exact substance naming and effective dates. Detection-window or masking guidance would serve a different purpose and will not be published.

Why this boundary was fixed at the start

The site could attract traffic with dosing and sourcing content, but those routes would contradict its evidence and consumer-protection purpose. We recorded the exclusions in the topical map before publishing compound profiles so later demand cannot quietly move the line.

Questions still deserve a route

A reader who already holds a vial should not reach a dead end. Testing, safety, UK regulation, sport status and official reporting routes provide practical next steps without a use protocol.

Go to safety questions and safe-action routes

Evidence methodHow claims are assessedSee the rating inputs, verdict language and rules for uncertainty. Commercial positionFunding and conflictsCheck which seller relationships and paid placements are excluded. Safe actionWhere to go for safety questionsSeparate known harms, suspected signals and unmeasured risk.

Editorial experience

From our work: how we checked this page

For topical-map item C-034, What we do not publish, and why was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 0 unique external sources and 4 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.

Yianni Kiromitis checked the page against its mapped purpose, verified the cited sources, reviewed the internal routes and approved the final wording as Lead Author, Publisher and Managing Editor. This page does not carry a specialist review credit because its publication decision did not require a scientific or clinical conclusion beyond the named material it links to.

We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.

Authorship

Written and edited by Yianni Kiromitis

Yianni Kiromitis, BSc (Hons) Radiography, PgC Medical Ultrasound (General Imaging), HCPC RA38415, is Lead Author, Publisher and Managing Editor. He is responsible for research, source verification, editorial decisions and correction management.

Publication approval

Yianni Kiromitis approved this page for publication on 10 August 2026 within his remit as Lead Author, Publisher and Managing Editor. Specialist reviewer credits appear only where a named reviewer completed work within that remit.

See the full author biographies and review remits